...
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD
【24h】

Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD

机译:UCSD自体和异基因造血干细胞移植后使用G-CSF的临床实践的回顾和修订

获取原文
获取原文并翻译 | 示例
           

摘要

There was no consensus on the optimal use of G-CSF after hematopoietic stem cell transplantation. In this study, the practice of using G-CSF, based on the CD34 + cell number, at the University of California, San Diego Blood and Marrow Transplant Unit (UCSD BMT) was evaluated by performing a five-year retrospective analysis of data from patients undergoing autologous and allogeneic transplantation. Various outcomes, such as time to neutrophil and platelet engraftment and length of post-transplant hospital stay are assessed in relation to use of G-CSF and number of CD34 + cells infused. It has been found that the use of G-CSF is associated with faster neutrophil engraftment and shorter length of post-transplant hospital stay without affecting time to platelet engraftment in patients undergoing autologous transplantation. In addition, the number of CD34 + cells do not influence outcomes in autologous and allogeneic transplant patients if they are treated with G-CSF. As a result of this evaluation, the G-CSF protocol at UCSD BMT Unit is revised. The main change is to implement the use of G-CSF in all patients undergoing autologous transplantation regardless of the number of CD34 + cells. No changes in the allogeneic transplantation protocol are made as a result of this analysis.
机译:造血干细胞移植后最佳使用G-CSF尚无共识。在这项研究中,加州大学圣地亚哥分校血液和骨髓移植科(UCSD BMT)根据CD34 +细胞数,使用G-CSF的做法是通过对数据的五年回顾性分析来评估的自体和异体移植的患者。评估各种结果,例如中性粒细胞和血小板的植入时间以及移植后住院时间的长短,与G-CSF的使用和注入的CD34 +细胞数量有关。已经发现,使用G-CSF与中性粒细胞植入更快,移植后住院时间较短而不影响自体移植患者血小板植入的时间有关。此外,如果接受G-CSF治疗,则CD34 +细胞的数量不会影响自体和异体移植患者的预后。评估的结果是,修改了UCSD BMT单元的G-CSF协议。主要变化是在所有接受自体移植的患者中均使用G-CSF,而与CD34 +细胞的数量无关。此分析的结果是,同种异体移植方案没有任何变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号